These past few months, cancer immunotherapy has sped-up thanks to CAR technology. One look at the recent news about this is enough to figure that out. As examples:
  • Two major deals between pharmaceutical companies and biotechs specialized in CAR T-cells: Gilead bought Kite Pharma for $12 billion, and Celgene bought Juno Therapeutics for $9 billion.
  • The Food and Drug Administration – FDA – has approved two immunotherapydrugs based on CAR T-cells technology:  Kymriah (Novartis) and Yescarta(Gilead).

Just this month, Cellectis has published a study in the journal Scientific Reports describing technological advances that could improve the safety of CAR-T cell therapies and US FDA approved Cellectis “off-the-shelf” CAR T-cell candidate, UCART22, for clinical trials.

CAR T-cells is heavily depending of technologies to genetically modify T-cells. The best strategy is based on the use of Lentiviral Vectors because they offer the bestefficiency/biosafety ratio. However, these two points have to be further improved to resolve many other challenges in immunotherapy and make CAR technology more extensively available for cancer therapy.

GEG Tech is widely committed in the field of CAR T-cells and provides standard CAR lentiviral vector systems as well as new and complex CAR systems. Furthermore, GEG Tech’s R&D team works hard to design the next generations of lentiviral vectors to genetically modify T-cells with a higher efficiency and level of biosafety.

We would like to thank our CAR customers for all the positive feedbacks, and hope we will soon have some news about our next generations of CAR lentiviral vector.

Feel free to contact us for any new CAR projects, we enjoy working in this exciting field!


Also published on Medium.

Leave a Comments